This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental material
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sánchez Negrette, O.
Right arrow Articles by Basombrío, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sánchez Negrette, O.
Right arrow Articles by Basombrío, M. A.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, February 2008, p. 297-302, Vol. 15, No. 2
1071-412X/08/$08.00+0     doi:10.1128/CVI.00106-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Serological Evaluation of Specific-Antibody Levels in Patients Treated for Chronic Chagas' Disease{triangledown},{dagger}

Olga Sánchez Negrette,* Fernando J. Sánchez Valdéz, Carlos D. Lacunza, María Fernanda García Bustos, María Celia Mora, Alejandro D. Uncos, and Miguel Ángel Basombrío

Instituto de Patología Experimental, Facultad de Ciencias de la Salud, Universidad Nacional de Salta, calle Buenos Aires 177, 4400 Salta, Argentina

Received 2 January 2007/ Returned for modification 27 April 2007/ Accepted 19 November 2007

Serological tests are the main laboratory procedures used for diagnosis during the indeterminate and chronic stages of Chagas' disease. A serological regression to negativity is the main criterion used to define parasitological cure in treated patients. The aim of this work was to monitor the individual specificities of antibody levels for 3 years posttreatment in 18 adult patients. Conventional serological techniques (hemagglutination assays and enzyme-linked immunosorbent assay [ELISA]) were modified by using recombinant antigens to detect early markers of treatment effectiveness. For this purpose, serum samples were taken before and during treatment and every 6 months after treatment for at least 3 years. When hemagglutination assays were used, a decrease in antibody levels was observed in only one patient. When ELISA with serum dilutions was used, antibody clearance became much more apparent: in 77.7% (14/18) of the patients, antibody titers became negative with time. This was observed at serum dilutions of 1/320 and occurred between the 6th and the 30th months posttreatment. The immune response and the interval for a serological regression to negativity were different for each patient. For some of the recombinant antigens, only 50% (9/18) of the patients reached the serological regression to negativity. Recombinant antigen 13 might be a good marker of treatment effectiveness, since 66.6% (six of nine) of the patients presented with an early regression to negativity for specific antibodies to this antigen (P = 0.002).

* Corresponding author. Mailing address: Instituto de Patología Experimental, Facultad de Ciencias de la Salud, Universidad Nacional de Salta, calle Buenos Aires 177, 4400 Salta, Argentina. Phone and fax: 54-387-4255333. E-mail: olgasanette{at}yahoo.com.ar

{triangledown} Published ahead of print on 5 December 2007.

{dagger} Supplemental material for this article may be found at http://cvi.asm.org/.

Clinical and Vaccine Immunology, February 2008, p. 297-302, Vol. 15, No. 2
1071-412X/08/$08.00+0     doi:10.1128/CVI.00106-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»